Catalan
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
amyotrophic lateral sclerosis/nicotina
L'enllaç es desa al porta-retalls
Pàgina 1 des de 16 resultats
Aminoadamantane derivatives as therapeutic agents
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
Aminoadamantane derivatives as therapeutic agents
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
Aminoadamantane derivatives as therapeutic agents
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
Certain adamantane derivatives have been used to treat illnesses. Rimantadine (1-(1-aminoethyl)adamantane) is used for the prophylaxis and treatment of influenza in humans. Amantadine has been used for the treatment of both influenza and Parkinson's disease (Schwab et
Thieno-pyridine derivatives as allosteric enhancers of the GABA.sub.B receptors
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
PRIORITY TO RELATED APPLICATIONS
This application claims the benefit of European Application No. 04106665.5, filed Dec. 17, 2004, which is hereby incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
.gamma.-Aminobutyric acid (GABA), the most abundant inhibitory neurotransmitter,
Phenyl-substituted nicotinic ligands, and methods of use thereof
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the
Phenyl-substituted nicotinic ligands, and methods of use thereof
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
BACKGROUND OF THE INVENTION
Neuronal nicotinic acetylcholine receptors (nAChRs) serve a wide range of physiological functions and have been implicated in a number of pathological processes and pharmacological effects of nicotinic drugs. Many of the important in vivo effects of nicotine in the
Urea compounds and their use as enzyme inhibitors
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION
The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty
Urea compounds and their use as enzyme inhibitors
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION
The present invention relates to compounds and their uses, and in particular to compounds and their therapeutic use in the treatment or prevention of conditions having an association with substrates, such as the neurotransmitter anandamide, which are broken down by the fatty
Triazinedione derivatives as GABA.sub.B receptor modulators
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
SUMMARY OF THE INVENTION
##STR00002##
The present invention provides novel compounds of formula I wherein W.sub.1, W.sub.2, W.sub.3, W.sub.4, W.sub.5, B, X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, E and L are as defined herein; invention compounds are gamma amino butyric acid receptor-subtype B
Triazinedione derivatives as GABA.sub.B receptor modulators
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
SUMMARY OF THE INVENTION
##STR00002##
The present invention provides novel compounds of formula I wherein W.sub.1, W.sub.2, W.sub.3, W.sub.4, W.sub.5, B, X.sub.1, X.sub.2, X.sub.3, X.sub.4, X.sub.5, E and L are as defined herein; invention compounds are gamma amino butyric acid receptor-subtype B
6H-oxazolo[4,5 e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The invention relates to 6H-oxazolo[4,5-e]indole derivatives of the formula I
##STR00002## in which R.sup.1 is H or Het.sup.1, R.sup.2 is H, A, cycloalkyl, --(CH.sub.2).sub.p--N(R.sup.5).sub.2, --(CH.sub.2).sub.p--OR.sup.5, --(CH.sub.2).sub.n--Ar or --(CH.sub.2).sub.n-Het, R.sup.3 is H, Hal, OH, OA
6H-oxazolo[4,5-e]indole derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The invention relates to 6H-oxazolo[4,5-e]indole derivatives of the formula I
##STR00002## in which
R.sup.1 is H or Het.sup.1,
R.sup.2 is H, A, cycloalkyl, --(CH.sub.2).sub.p--N(R.sup.5).sub.2, --(CH.sub.2).sub.p--OR.sup.5, --(CH.sub.2).sub.n--Ar or --(CH.sub.2).sub.n-Het,
R.sup.3 is H, Hal, OH, OA
Dihydroimidazo[4,5-e]indole and 7h-pyrrolo[3,2-f]quinoxaline derivatives as nicotinic acetylcholine receptor ligands and/or serotonergic ligands
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
The invention relates to dihydroimidazo[4,5-e]indole and 7H-pyrrolo-[3,2-]quinoxaline derivatives of the formula I
##STR00002## in which A-B-D is --NR.sup.6--CR.sup.2.dbd.N--, --N.dbd.CR.sup.2--NR.sup.6-- or --N.dbd.CR.sup.7--CR.sup.8.dbd.N--, R.sup.1 is H or Het.sup.1, R.sup.2 is H, A, cycloalkyl,
Cytokine antagonists for neurological and neuropsychiatric disorders
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION
The present invention relates to novel methods of use of specific cytokine antagonists for the treatment of neuropsychiatric and neurological disorders in humans. More particularly, these cytokine antagonists are used in a new treatment of neuropsychiatric and neurologic
Cytokine antagonists for neurological and neuropsychiatric disorders
Només els usuaris registrats poden traduir articles
Inicieu sessió / registreu-vos
FIELD OF THE INVENTION
The present invention relates to novel methods of use of specific cytokine antagonists for the treatment of neuropsychiatric and neurological disorders in humans. More particularly, these cytokine antagonists are used in a new treatment of neuropsychiatric and neurologic
La base de dades d’herbes medicinals més completa avalada per la ciència
- Funciona en 55 idiomes
- Cures a base d'herbes recolzades per la ciència
- Reconeixement d’herbes per imatge
- Mapa GPS interactiu: etiqueta les herbes a la ubicació (properament)
- Llegiu publicacions científiques relacionades amb la vostra cerca
- Cerqueu herbes medicinals pels seus efectes
- Organitzeu els vostres interessos i estigueu al dia de les novetats, els assajos clínics i les patents
Escriviu un símptoma o una malaltia i llegiu sobre herbes que us poden ajudar, escriviu una herba i vegeu malalties i símptomes contra els quals s’utilitza.
* Tota la informació es basa en investigacions científiques publicades
